Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

BTAI

BioXcel Therapeutics Inc

Jun 25 • 04:00PM ET

1.18

Dollar change -0.01
Percentage change -0.84	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO SCHA VTWO IWC VTWG SCHB RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.18	Insider Own	21.88%	Shs Outstand	29.93M	Perf Week	-11.28%
Market Cap	44.29M	Forward P/E	-	EPS next Y	-1.71	Insider Trans	-3.13%	Shs Float	29.32M	Perf Month	-36.22%
Income	-153.05M	PEG	-	EPS next Q	-0.71	Inst Own	24.92%	Short Float	5.06%	Perf Quarter	-58.60%
Sales	1.76M	P/S	25.16	EPS this Y	57.92%	Inst Trans	-4.57%	Short Ratio	2.87	Perf Half Y	-60.27%
Book/sh	-2.15	P/B	-	EPS next Y	33.87%	ROA	-116.64%	Short Interest	1.48M	Perf Year	-93.74%
Cash/sh	1.98	P/C	0.60	EPS next 5Y	-	ROE	-1766.94%	52W Range	1.11 - 19.07	Perf YTD	-60.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-35.97%	ROI	-516.70%	52W High	-93.81%	Beta	0.32
Dividend TTM	-	Quick Ratio	2.49	Sales past 5Y	53.60%	Gross Margin	2.05%	52W Low	6.31%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	2.57	EPS Y/Y TTM	21.90%	Oper. Margin	-7933.20%	RSI (14)	21.34	Volatility	8.79% 7.65%
Employees	74	Debt/Eq	-	Sales Y/Y TTM	202.24%	Profit Margin	-8715.72%	Recom	1.80	Target Price	6.30
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	52.96%	Payout	-	Rel Volume	1.45	Prev Close	1.19
Sales Surprise	29.33%	EPS Surprise	-28.91%	Sales Q/Q	182.52%	Earnings	May 09 BMO	Avg Volume	517.49K	Price	1.18
SMA20	-21.53%	SMA50	-42.54%	SMA200	-59.33%	Trades		Volume	750,296	Change	-0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-21-24	Downgrade	UBS	Buy → Neutral	$9 → $4
Aug-15-23	Downgrade	Mizuho	Buy → Neutral	$40 → $4
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold	$20 → $22
Dec-01-22	Upgrade	Goldman	Sell → Neutral	$16
Jul-07-22	Initiated	Mizuho	Buy	$19
Apr-06-22	Reiterated	BofA Securities	Buy	$80
Nov-15-21	Downgrade	Goldman	Neutral → Sell	$55 → $24
Apr-09-21	Initiated	Berenberg	Buy	$75
Feb-01-21	Initiated	UBS	Buy	$99
Oct-30-20	Initiated	Goldman	Buy	$60
Sep-02-20	Initiated	Jefferies	Buy	$82
Aug-17-20	Reiterated	H.C. Wainwright	Buy	$200 → $175
Jul-08-20	Reiterated	H.C. Wainwright	Buy	$95 → $120
Jun-04-20	Initiated	Guggenheim	Buy	$101
Apr-01-20	Initiated	BofA/Merrill	Buy	$45
Feb-26-20	Reiterated	H.C. Wainwright	Buy	$30 → $95
Jan-08-20	Reiterated	H.C. Wainwright	Buy	$25 → $30
Nov-12-19	Initiated	SunTrust	Buy	$24

Show Previous Ratings

Today 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
May-28-24 07:00AM	BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-24 07:00AM	BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (GlobeNewswire)
May-10-24 11:58AM	BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript (Insider Monkey) -9.33%
11:31PM	Loading…
May-09-24 11:31PM	Q1 2024 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +8.73%
11:58AM	BTAI Stock Earnings: BioXcel Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	BioXcel Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 07:00AM	BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-24-24 10:30AM	BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting (GlobeNewswire) -8.75%
Apr-22-24 07:00AM	BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential (GlobeNewswire)
Apr-10-24 07:00AM	BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia (GlobeNewswire)
Mar-25-24 07:00AM	BioXcel Therapeutics Announces $25 Million Registered Direct Offering (GlobeNewswire)
Mar-15-24 07:00AM	BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine (GlobeNewswire) -6.62%
Mar-13-24 08:57AM	BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:48PM	Loading…
Mar-12-24 09:48PM	Q4 2023 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Mar-07-24 02:52PM	7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode (InvestorPlace)
Mar-01-24 07:00AM	BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 (GlobeNewswire)
Feb-22-24 12:58PM	15 Hot Penny Stocks On the Move (Insider Monkey)
Feb-14-24 08:30AM	Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies (GlobeNewswire) +26.02%
Feb-13-24 09:00AM	BioXcel Therapeutics Announces Termination of Proposed Public Offering (GlobeNewswire) +26.15%
Feb-12-24 07:14AM	BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) (GlobeNewswire) -7.58%
Feb-09-24 09:05AM	Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today? (InvestorPlace) -43.73%
Feb-08-24 04:01PM	BioXcel Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Feb-06-24 07:00AM	BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA (GlobeNewswire) +8.89%
Feb-05-24 07:00AM	BioXcel Therapeutics Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine (GlobeNewswire) +21.24%
Dec-12-23 07:00AM	BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today (GlobeNewswire)
Dec-11-23 07:00AM	BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs (GlobeNewswire)
Dec-01-23 07:29PM	Moore Kuehn, PLLC Encourages BioXcel Therapeutics, Inc. Investors to Contact Law Firm (PR Newswire)
07:00AM	Loading…
Nov-30-23 07:00AM	BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023 (GlobeNewswire)
Nov-24-23 06:40AM	7 Penny Stocks With Low Floats and High Short Interest (InvestorPlace)
Nov-15-23 02:23PM	BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript (Insider Monkey)
02:27AM	Q3 2023 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 07:52AM	BioXcel Therapeutics Inc (BTAI) Reports Q3 2023 Financial Results and Strategic Updates (GuruFocus.com) -23.41%
07:00AM	BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-08-23 07:00AM	BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype (GlobeNewswire)
Nov-06-23 07:00AM	BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD) (GlobeNewswire)
Oct-31-23 07:00AM	BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023 (GlobeNewswire)
Oct-30-23 07:00AM	BioXcel Therapeutics Receives Permanent J-Code for IGALMI (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services (GlobeNewswire) +31.68%
Oct-25-23 09:18AM	Why Is BioXcel Therapeutics (BTAI) Stock Up 42% Today? (InvestorPlace) +20.94%
07:00AM	BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site (GlobeNewswire)
Oct-17-23 10:26AM	BTAI: BXCL701 Shows Positive Overall Survival Results in Phase 2 Trial (Zacks)
Oct-10-23 09:45AM	Investors in BioXcel Therapeutics, Inc. (NASDAQ: BTAI) should contact the Shareholders Foundation in connection with a Lawsuit (GlobeNewswire) +21.53%
07:00AM	BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer (GlobeNewswire)
Oct-04-23 07:00AM	BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI (dexmedetomidine) Sublingual Film (GlobeNewswire) +13.25%
Sep-28-23 05:35PM	Why Shares of BioXcel Therapeutics Fell This Week (Motley Fool) -9.12%
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey)
Aug-17-23 10:30AM	BTAI: Strategic Reprioritization Underway... (Zacks) +5.04%
Aug-15-23 05:43PM	Why BioXcel Therapeutics Stock Flopped Again Today (Motley Fool)
09:59AM	Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls (The Fly)
Aug-14-23 11:04PM	Q2 2023 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -41.49%
12:44PM	3 Biotech Stocks to Sell in August Before They Crash and Burn (InvestorPlace)
12:01PM	Why BioXcel Therapeutics Stock Is Getting Crushed Today (Motley Fool)
07:24AM	BioXcel cuts over 50% jobs as it pivots focus to retail market for agitation drug (Reuters)
07:21AM	UPDATE 2-BioXcel to cut over 50% of jobs as it pivots focus to agitation drug (Reuters)
07:06AM	BioXcel announces job cuts (Reuters)
07:00AM	BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization (GlobeNewswire)
Jul-31-23 07:00AM	BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023 (GlobeNewswire)
Jul-07-23 08:16AM	Why BioXcel Therapeutics Stock Was Bouncing Back This Week (Motley Fool) -6.53%
Jul-05-23 10:20AM	BTAI: Positive Data for TRANQUILITY II Trial Overshadowed by Possible Trial Mismanagement (Zacks Small Cap Research) +42.26%
Jun-29-23 04:12PM	BioXcel Stock Craters 64% As Fraud Investigation Erases Its 'Huge Win' In Alzheimer's Study (Investor's Business Daily) -63.84%
11:33AM	Why Shares of BioXcel Therapeutics Are Plunging Thursday (Motley Fool)
06:04AM	BioXcel Therapeutics's drug meets key trial goal to treat Alzheimer's patients (Reuters)
06:00AM	BioXcel CEO Vimal Mehta Says This Alzheimer's News Is A 'Huge Win For Society' (Investor's Business Daily)
06:00AM	BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimers Disease-Related Agitation (GlobeNewswire)
Jun-15-23 09:46PM	3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally (InvestorPlace) -6.47%
Jun-02-23 06:20AM	BTAI: Promising Results for Part 1 of SERENITY III Trial (Zacks Small Cap Research)
Jun-01-23 07:00AM	BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-25-23 04:03PM	BioXcel Stock Crashes 25% As Bid To Double Its Market Appears Less Certain (Investor's Business Daily) -25.49%
03:10PM	BioXcel Therapeutics Stock Tumbles: Company Releases Mixed Results From Lower Dose Igalmi Study In Bipolar/Schizophrenia Associated Agitation (Benzinga)
12:40PM	Why Shares of BioXcel Therapeutics Are Dropping Thursday (Motley Fool)
07:00AM	BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia (GlobeNewswire)
May-16-23 07:00AM	BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program (GlobeNewswire)
May-11-23 03:13PM	Why These 3 Nasdaq Stocks Were Glowing Green This Week (Motley Fool) -5.28%
10:20AM	BTAI: Three Data Readouts Expected in the Near Term (Zacks Small Cap Research)
May-09-23 02:03AM	Q1 2023 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 04:54PM	Why BioXcel Therapeutics Stock Marched Higher Today (Motley Fool) +13.64%
04:07PM	Highly Rated Axsome Surges On Earnings Beat. And Here's Why BioXcel Reversed. (Investor's Business Daily)
09:25AM	Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite. (Investor's Business Daily)
07:00AM	BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights (GlobeNewswire)
May-04-23 08:00AM	The Next Evolution In Drugs? It's Artificial Intelligence, Says This CEO (Investor's Business Daily)
May-02-23 07:00AM	BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference (GlobeNewswire)
Apr-24-23 07:00AM	BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023 (GlobeNewswire)
Mar-22-23 08:21AM	BTAI: Important Data Readouts in 2Q23 (Zacks Small Cap Research) -7.90%
Mar-14-23 04:15PM	OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering (GlobeNewswire) -5.35%
Mar-11-23 09:25AM	BioXcel Therapeutics, Inc. (NASDAQ:BTAI): When Will It Breakeven? (Simply Wall St.)
Mar-10-23 02:32AM	Q4 2022 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -15.88%
Mar-09-23 07:00AM	BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights (GlobeNewswire) -13.40%
Feb-23-23 07:00AM	BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023 (GlobeNewswire) +6.71%
Feb-21-23 07:00AM	BioXcel Therapeutics to Ring Nasdaq Stock Market Closing Bell Today (GlobeNewswire)
Feb-14-23 09:50AM	BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype (Benzinga)
Feb-13-23 05:00PM	BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium (GlobeNewswire)
Feb-08-23 02:27PM	Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023 (Benzinga) +8.31%
07:00AM	BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Companys Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer (GlobeNewswire)
Jan-27-23 07:00AM	BTAI: Multiple Catalysts Ahead in 2023 (Zacks Small Cap Research)
Jan-11-23 07:00AM	BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer (GlobeNewswire)
Dec-27-22 07:34AM	A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy (Simply Wall St.)
Dec-22-22 07:00AM	BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.25%
Dec-19-22 07:00AM	BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimers Disease (GlobeNewswire)

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mehta Vimal	CEO and President	Jun 17 '24	Sale	1.28	2,134	2,739	47,539	Jun 18 09:24 PM
Yocca Frank	Chief Scientific Officer	Jun 17 '24	Sale	1.28	372	476	13,474	Jun 18 09:27 PM
Steinhart Richard I	Chief Financial Officer	Jun 17 '24	Sale	1.26	372	470	5,476	Jun 18 09:26 PM
Rodriguez Javier	See Remarks	Jun 17 '24	Sale	1.26	361	456	8,394	Jun 18 09:25 PM
Wiley Matthew T.	Chief Commercial Officer	Jun 17 '24	Sale	1.26	244	308	3,498	Jun 18 09:26 PM
O'Neill Vincent	See Remarks	Jun 17 '24	Sale	1.28	155	199	3,524	Jun 18 09:25 PM
Mehta Vimal	CEO and President	Jun 05 '24	Sale	1.58	126,014	199,619	7,685,501	Jun 06 08:35 PM
Mehta Vimal	CEO and President	Jun 04 '24	Sale	1.63	126,014	205,516	7,811,515	Jun 06 08:35 PM
Mehta Vimal	CEO and President	Apr 04 '24	Sale	2.62	5,268	13,823	43,564	Apr 08 07:32 PM
Steinhart Richard I	Chief Financial Officer	Apr 04 '24	Sale	2.63	1,069	2,817	4,765	Apr 08 07:32 PM
Yocca Frank	Chief Scientific Officer	Apr 04 '24	Sale	2.63	1,067	2,812	12,763	Apr 08 07:30 PM
Rodriguez Javier	See Remarks	Apr 04 '24	Sale	2.64	1,012	2,667	7,672	Apr 08 07:30 PM
Wiley Matthew T.	CHIEF COMMERCIAL OFFICER	Apr 04 '24	Sale	2.64	1,008	2,656	2,992	Apr 08 07:31 PM
O'Neill Vincent	See Remarks	Apr 04 '24	Sale	2.62	165	432	5,408	Apr 08 07:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BTAI

BioXcel Therapeutics Inc

Upgrade your FINVIZ experience